349 related articles for article (PubMed ID: 34358160)
1. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
2. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
4. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
[TBL] [Abstract][Full Text] [Related]
5. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
6. Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Rattanapisit K; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Prompetchara E; Ketloy C; Buranapraditkun S; Wijagkanalan W; Tharakhet K; Kaewpang P; Leetanasaksakul K; Kemthong T; Suttisan N; Malaivijitnond S; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Front Plant Sci; 2021; 12():682953. PubMed ID: 34054909
[TBL] [Abstract][Full Text] [Related]
7. Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2.
Shi J; Zhao Y; Peng M; Zhu S; Wu Y; Ji R; Shen C
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112625
[TBL] [Abstract][Full Text] [Related]
8. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
9. Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice.
Özcengiz E; Keser D; Özcengiz G; Çelik G; Özkul A; İnçeh FN
Immun Inflamm Dis; 2022 Dec; 10(12):e748. PubMed ID: 36444622
[TBL] [Abstract][Full Text] [Related]
10. Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine.
Dashti N; Golsaz-Shirazi F; Soltanghoraee H; Zarnani AH; Mohammadi M; Imani D; Jeddi-Tehrani M; Amiri MM; Shokri F
Eur J Microbiol Immunol (Bp); 2024 May; ():. PubMed ID: 38753442
[TBL] [Abstract][Full Text] [Related]
11. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant.
Zhang N; Ji Q; Liu Z; Tang K; Xie Y; Li K; Zhou J; Li S; Shang H; Shi Z; Zheng T; Yao J; Lu L; Yuan S; Jiang S
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336907
[TBL] [Abstract][Full Text] [Related]
12. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
13. Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).
Kumru OS; Bajoria S; Kaur K; Hickey JM; Van Slyke G; Doering J; Berman K; Richardson C; Lien H; Kleanthous H; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2023 Aug; 19(2):2264594. PubMed ID: 37932241
[TBL] [Abstract][Full Text] [Related]
14. Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle.
Royal JM; Simpson CA; McCormick AA; Phillips A; Hume S; Morton J; Shepherd J; Oh Y; Swope K; DeBeauchamp JL; Webby RJ; Cross RW; Borisevich V; Geisbert TW; Demarco JK; Bratcher B; Haydon H; Pogue GP
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835278
[TBL] [Abstract][Full Text] [Related]
15. Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; Dâ Aquino AI; Pulendran B; Kim PS; Appel EA
bioRxiv; 2021 Aug; ():. PubMed ID: 33821276
[TBL] [Abstract][Full Text] [Related]
16. Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist.
Wang XF; Zhang MJ; He N; Wang YC; Yan C; Chen XZ; Gao XF; Guo J; Luo R; Liu Z
J Med Chem; 2021 Aug; 64(15):11554-11569. PubMed ID: 34279930
[TBL] [Abstract][Full Text] [Related]
17. The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation.
George PJ; Tai W; Du L; Lustigman S
Vaccines (Basel); 2020 May; 8(2):. PubMed ID: 32471056
[TBL] [Abstract][Full Text] [Related]
18. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
[TBL] [Abstract][Full Text] [Related]
19. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S; Fakharzadeh S; Karimi P; Hafizi M; Jamaati H; Hassanzadeh SM; Khorasani A; Mahdavi M; Nazaran MH
Viral Immunol; 2023; 36(6):409-423. PubMed ID: 37506342
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.
Haghighi M; Khorasani A; Karimi P; Mahdavi M
Iran J Basic Med Sci; 2022 May; 25(5):554-561. PubMed ID: 35911642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
